Nutcracker announces key C-suite hires, unveils pipeline

22 June 2022

Just three months after Nutcracker Therapeutics’ announcement of receiving $167 million in Series C funding, three new leadership positions have been filled alongside the release of its oncology and disease-focused pipeline.

Recent hires:

John Stubenrauch joins as chief operating officerwith 25 years of experience in leadership roles across the biopharma industry. Most recently, he served as vice president of biologics commercial operations at Gilead Sciences following the acquisition of Immunodemics, where he was senior vice president of manufacturing. He’ll be strengthening Nutcracker’s operational development while also overseeing therapeutic manufacturing, quality control, and supply management.
Geoff Nostrati as chief business officer(CBO), will be overseeing business development and corporate strategy functions. Mr Nostrati most recently served as CBO at Immunoscape.
Ian Weineras general counsel, will be advising the board and management on legal, business and policy matters. Weiner was previously a partner at Irell & Manella LLP.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK